Research Analysts’ Recent Ratings Changes for Ekso Bionics (EKSO)

Several brokerages have updated their recommendations and price targets on shares of Ekso Bionics (NASDAQ: EKSO) in the last few weeks:

• 1/14/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/14/2025 – Ekso Bionics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
• 1/6/2025 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/29/2024 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/21/2024 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/13/2024 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/5/2024 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/27/2024 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/19/2024 – Ekso Bionics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Ekso Bionics Price Performance

Shares of EKSO opened at $0.65 on Thursday. The firm has a market cap of $14.30 million, a PE ratio of -1.00 and a beta of 1.47. Ekso Bionics Holdings, Inc. has a 52-week low of $0.50 and a 52-week high of $2.50. The business’s 50 day moving average price is $0.69 and its two-hundred day moving average price is $0.95. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The company had revenue of $4.13 million for the quarter, compared to analyst estimates of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same quarter in the previous year, the firm earned ($0.24) EPS. On average, equities analysts anticipate that Ekso Bionics Holdings, Inc. will post -0.48 EPS for the current year.

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.